Institution
Central Drug Research Institute
Facility•Lucknow, Uttar Pradesh, India•
About: Central Drug Research Institute is a facility organization based out in Lucknow, Uttar Pradesh, India. It is known for research contribution in the topics: Catalysis & Leishmania donovani. The organization has 4357 authors who have published 7257 publications receiving 143871 citations. The organization is also known as: Central Drug Research Institute, Lucknow & CDRI.
Topics: Catalysis, Leishmania donovani, Ring (chemistry), Aryl, Apoptosis
Papers published on a yearly basis
Papers
More filters
••
TL;DR: This review attempted to provide a comprehensive profile of key miRNAs involved in ovarian carcinoma to establish mi RNAs as more reliable non-invasive clinical biomarkers for early detection of ovarian cancer compared with protein and DNA biomarkers.
Abstract: Epithelial ovarian cancer (EOC) is the leading cause of death among all gynecological malignancies. Despite the technological and medical advances over the past four decades, such as the development of several biological markers (mRNA and proteins biomarkers), the mortality rate of ovarian cancer remains a challenge because of its late diagnosis, which is specifically attributed to low specificities and sensitivities. Under this compulsive scenario, recent advances in expression biology have shifted in identifying and developing specific and sensitive biomarkers, such as microRNAs (miRNAs) for cancer diagnosis and prognosis. MiRNAs are a novel class of small non-coding RNAs that deregulate gene expression at the posttranscriptional level, either by translational repression or by mRNA degradation. These mechanisms may be involved in a complex cascade of cellular events associated with the pathophysiology of many types of cancer. MiRNAs are easily detectable in tissue and blood samples of cancer patients. Therefore, miRNAs hold good promise as potential biomarkers in ovarian cancer. In this review, we attempted to provide a comprehensive profile of key miRNAs involved in ovarian carcinoma to establish miRNAs as more reliable non-invasive clinical biomarkers for early detection of ovarian cancer compared with protein and DNA biomarkers.
84 citations
••
TL;DR: Observations suggest that Noni may be useful in memory impairment due to its effect on CBF, AChE and oxidative stress.
84 citations
••
TL;DR: The mechanism of action, preclinical and clinical trial data of the agents that are in use for targeting the EGFR/HER‐2 pathway and the current status and the future clinical trial promises of these agents have been pondered to provide better and more efficacious treatment strategies for breast cancer patients.
Abstract: Breast cancer is the most common cancer diagnosed in women and the second most common cause of female cancer-related deaths, with more than one million new cases diagnosed per year throughout the world. With the recent advances in the knowledge of cellular processes and signaling pathways involved in the pathogenesis of breast cancer, the current focus of researchers and clinicians is to develop novel treatment strategies that can be included in the armamentarium against breast cancer. With the failure of endocrine-targeted therapy and the development of resistance to existing chemotherapy, the most explored pathway as next generation target for breast cancer therapy has been the epidermal growth factor receptor (EGFR) (ErbB-1)/herceptin-2 (HER-2) (ErbB-2) pathway. This review focuses on the rationale for targeting members of ErbB receptor family and numerous agents that are in use for inhibiting the pathway. The mechanism of action, preclinical and clinical trial data of the agents that are in use for targeting the EGFR/HER-2 pathway and the current status, thereof, have been discussed in detail. In addition, the future clinical trial promises these agents hold either as monotherapy or as combination therapy with conventional agents or with other antisignaling agents have been pondered, so as to provide better and more efficacious treatment strategies for breast cancer patients.
84 citations
••
TL;DR: The present investigation demonstrates the hepatoprotective potential of 50% ethanolic water extract of whole plant of Fumaria indica and its three fractions viz., hexane, chloroform and butanol against d-galactosamine induced hepatotoxicity in rats.
84 citations
••
TL;DR: The results suggest the effective use of an in vitro test system as an alternative for in vivo assessment of hepatoprotective activity of purified material.
Abstract: Ursolic acid is the active material isolated from the leaves of the Eucalyptus hybrid E. tereticornis. In the present study, it has shown a significant preventive effect in vitro against ethanol-induced toxicity in isolated rat hepatocytes. Compared with the incubation of isolated hepatocytes with ethanol only, the simultaneous presence of ursolic acid in the cell suspension preserved the viability of hepatocytes and reversed the ethanol-induced loss in the level of all the marker enzymes (AST, ALT and AP) studied. Ethanol alone resulted in a 48%-54% decrease in the viability and a 42%-54% reduction in the biochemical parameters of the hepatocytes. Ursolic acid showed a concentration dependent (1-100 microg/mL) preventive effect (12%-76%) on alcohol-induced hepatocyte toxicity by restoring the altered parameters. The results thus suggest the effective use of an in vitro test system as an alternative for in vivo assessment of hepatoprotective activity of purified material.
84 citations
Authors
Showing all 4385 results
Name | H-index | Papers | Citations |
---|---|---|---|
Sanjay Kumar | 120 | 2052 | 82620 |
John A. Katzenellenbogen | 95 | 691 | 36132 |
Brajesh K. Singh | 83 | 401 | 24101 |
Gaurav Sharma | 82 | 1244 | 31482 |
Sudhir Kumar | 82 | 524 | 216349 |
Pramod K. Srivastava | 79 | 390 | 27330 |
Mohan K. Raizada | 75 | 473 | 21452 |
Syed F. Ali | 71 | 446 | 18669 |
Ravi Shankar | 66 | 672 | 19326 |
Ramesh Chandra | 66 | 620 | 16293 |
Manoj Kumar | 65 | 408 | 16838 |
Manish Kumar | 61 | 1425 | 21762 |
Anil Kumar Saxena | 58 | 310 | 10107 |
Sanjay Krishna | 56 | 624 | 13731 |
Naibedya Chattopadhyay | 56 | 242 | 9795 |